📍 This Delaware-based branch will enhance its contract development and manufacturing organization (CDMO) services.
💼 The company has completed projects for nine biotech firms and recently signed a contract with Serpin Pharma for clinical manufacturing.
🚀 CEO Amir Reichman believes this move will significantly boost business prospects in the U.S.
Introduction:
The article discusses the establishment of a U.S. subsidiary by Scinai Immunotherapeutics, a company focused on the development of biological products related to inflammation and immunology. This new subsidiary, named Scinai Bioservices, is designed to enhance the company’s contract development and manufacturing organization (CDMO) services in the U.S. market.
- Scinai Immunotherapeutics has created a Delaware-based subsidiary called Scinai Bioservices to expand its CDMO services in the U.S.
- The CDMO business unit was launched earlier this year and operates from a facility in Jerusalem, featuring substantial clean room and laboratory space.
- Scinai has successfully completed drug development projects for several biotech companies, covering various aspects of drug manufacturing and development.
- The company has formed a partnership with Ayana Pharma to develop liposomal encapsulated drugs.
- Scinai recently signed its first contract with Serpin Pharma for clinical manufacturing, indicating positive initial engagement with the U.S. market.
Conclusion:
The launch of Scinai Bioservices marks a strategic effort by Scinai Immunotherapeutics to enhance its presence in the U.S. market, particularly in the competitive field of contract manufacturing. With a strong background in drug development and a recent partnership, the company is poised for growth and increased opportunities within the biotechnology sector. The initial contract with Serpin Pharma suggests a promising start for the new subsidiary, highlighting potential future collaborations and expansions in the U.S. market.
